bioRxivBiochemistryPreprint
The MASLD-causing E167K variant of TM6SF2 is degraded by the ubiquitin ligase RNF5
- Citations
- 0
Abstract
The TM6SF2 E167K loss-of-function variant is one of the most penetrant genetic risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD), including progression to cirrhosis and hepatocellular carcinoma. Here we show that TM6SF2 E167K is recognized and degraded by the ER-associated degradation pathway, and identify RNF5 as the ubiquitin ligase tagging TM6SF2 E167K, providing a rational target for MASLD therapy.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variant
L. A. P. Faccioli, Y. Sun, … A. Soto-Gutierrez·bioRxiv·Dec 18, 2023
- MTARC1 Regulates Lipid Droplet Degradation via Phospholipid Remodeling in Metabolic Fatty Liver Disease
- Induction of TFEB promotes Kupffer cell survival and reduces lipid accumulation and inflammation in MASLD
Mandy M. Chan, Sabine Daemen, … Joel D. Schilling·bioRxiv·Apr 19, 2025
- Perturbation of transmembrane 6 superfamily member 2 expression alters lipid metabolism in a human liver cell line
A. Pant, Y. Chen, … E. K. Speliotes·bioRxiv·Aug 4, 2021
- The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma
Danny Orabi, William J. Massey, … J. Mark Brown·bioRxiv·Jul 29, 2025
- TMPRSS6 Cleavage of β-Klotho Modulates FGF19 Signaling
Matthieu Lepage, Antoine Désilets, … Richard Leduc·bioRxiv·Aug 27, 2026